New Bemotrizinol Sunscreen Boost: FDA Calls for Comments
Published Date: 12/12/2025
Notice
Summary
The FDA is proposing a change to sunscreen rules to allow a new ingredient called bemotrizinol at up to 6% in over-the-counter sunscreens. This means sunscreen makers can use this ingredient once the rule is final, helping improve sun protection options. People and companies should send their thoughts by January 26, 2026, so the FDA can decide soon.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
GRASE Status for Bemotrizinol Products
If finalized, the proposed order would find that sunscreen drug products containing bemotrizinol are generally recognized as safe and effective (GRASE) when they meet the conditions set out in OTC Monograph M020. That determination would allow manufacturers to market bemotrizinol-containing OTC sunscreens under the monograph framework.
Bemotrizinol Allowed up to 6%
The FDA proposes adding bemotrizinol as an over-the-counter sunscreen active ingredient at concentrations up to 6 percent in OTC Monograph M020 if the proposed order (OTC000039) is finalized. This change would allow sunscreen products with bemotrizinol to be marketed under the OTC monograph conditions described in M020.
Permitted Dosage Forms and Spray Limits
The proposed order would permit bemotrizinol in specified dosage forms: oil, lotion, cream, gel, butter, paste, ointment, stick, and spray. Spray forms are allowed only if manufactured and packaged with no propellant or if any propellant is isolated from the drug formulation so there is no contact between propellant and the product formulation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-22648 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Title-National Incident-Based Reporting System (NIBRS)
The FBI wants to keep collecting crime data through the National Incident-Based Reporting System (NIBRS) and is asking for public feedback for 60 days until February 10, 2026. This helps law enforcement track crime better without adding extra paperwork stress. If you’re involved in crime reporting, your input can help make the process smoother and more useful!
Next: 2025-22650 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extension: Rule 17f-7
The SEC wants to keep the rules that help investment funds safely store their foreign assets with trusted banks. Funds and their advisers must get risk reports and have contracts ensuring ongoing risk checks. This update keeps protections strong without adding new costs or deadlines.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in